Patent to be granted in China regarding IntelliGel
The China National Intellectual Property Administration (CNIPA) has communicated its intention to grant a new patent in China in the portfolio licensed to Redwood Pharma from Broda International LLC. A new patent will, when granted, provide patent protection in China, one of the largest markets globally, for the IntelliGel platform, which is used, inter alia, in the development of Redwood Pharmas RP101 new candidate drug.China represents one of the largest global markets and opportunities for topical eye therapies using the IntelliGel drug delivery platform. This means that Redwood Pharma’s